Literature DB >> 8735098

Detection of quinolone-resistant Neisseria gonorrhoeae.

K M Kam1, P W Wong, M M Cheung, N K Ho.   

Abstract

The present National Committee for Clinical Laboratory Standards (NCCLS) guideline for testing Neisseria gonorrhoeae quinolone susceptibility defines only a susceptible category for ciprofloxacin, enoxacin, lomefloxacin, and ofloxacin, while susceptible, intermediate, and resistant categories are defined for fleroxacin. To further define the criteria for detection of quinolone resistance in gonococci, by standard disk diffusion and agar dilution methodologies recommended by the NCCLS, we tested 29 strains of quinolone-resistant N. gonorrhoeae (QRNG) recently isolated from ofloxacin-treated patients who were considered clinical failures. Regression analyses were performed on these results together with those of another 20 strains showing reduced susceptibility and 13 fully susceptible strains (ofloxacin MICs of < or = 0.25 microgram/ml). With 5-micrograms ofloxacin disks, resistance in 27 (93.1%) of the QRNG strains (MICs of > 1 microgram/ml) was detected by the criterion of a zone diameter of < 22 mm, while in the remaining 2 (6.9%), the disks failed to detect resistance. A cluster of 15 highly resistant strains showed ofloxacin MICs of > 4 micrograms/ml and zone diameters of < 13 mm. When tested with 5-micrograms ciprofloxacin disks, the corresponding values for resistance and high-level resistance of these QRNG strains were < 25 mm (MICs of > 0.5 micrograms/ml) and < 15 mm (MICs of > 2 micrograms /ml), respectively. Six strains for which ofloxacin MICs were > or = 8 micrograms/ml showed no zones at all with both 5-micrograms ofloxacin and 5-micrograms ciprofloxacin disks. These QRNG strains are now firmly established in the Southeast Asia region, and it is important for clinical laboratories to recognize these clinically resistant strains and to monitor their spread.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735098      PMCID: PMC229042          DOI: 10.1128/jcm.34.6.1462-1464.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Disk diffusion method for susceptibility testing of Neisseria gonorrhoeae.

Authors:  S Ringertz; M Rylander; G Kronvall
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

2.  Non-typable quinolone-resistant gonococci.

Authors:  H Young; A Moyes; I B Tait; A C McCartney; G Gallacher
Journal:  Lancet       Date:  1990-03-10       Impact factor: 79.321

3.  Ciprofloxacin resistance in gonococci.

Authors:  A E Jephcott; A Turner
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

4.  Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection.

Authors:  J R Black; J M Long; B E Zwickl; B S Ray; M S Verdon; S Wetherby; E W Hook; H H Handsfield
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

5.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

6.  Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.

Authors:  R N Jones; T L Gavan; C Thornsberry; P C Fuchs; E H Gerlach; J S Knapp; P Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

7.  Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin.

Authors:  P C Fuchs; A L Barry; C Baker; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

8.  A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis.

Authors:  J W Boslego; C B Hicks; R Greenup; R J Thomas; H A Wiener; J Ciak; E C Tramont
Journal:  Sex Transm Dis       Date:  1988 Oct-Dec       Impact factor: 2.830

9.  [Efficacy of ofloxacin in sexually transmitted male urethritis and cervicitis].

Authors:  Y Kumamoto; S Sakai; T Hirose; T Tsunekawa; T Machida; H Kiyota; T Okazaki; H Kishi; E Higashihara; Y Aso
Journal:  Jpn J Antibiot       Date:  1988-10

10.  Rapid decline in penicillinase-producing Neisseria gonorrhoeae in Hong Kong associated with emerging 4-fluoroquinolone resistance.

Authors:  K M Kam; K K Lo; N K Ho; M M Cheung
Journal:  Genitourin Med       Date:  1995-06
View more
  3 in total

Review 1.  Epidemiology of gonorrhoea: a global perspective.

Authors:  Robert D Kirkcaldy; Emily Weston; Aluisio C Segurado; Gwenda Hughes
Journal:  Sex Health       Date:  2019-09       Impact factor: 2.706

2.  Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test.

Authors:  A Hakanen; P Kotilainen; J Jalava; A Siitonen; P Huovinen
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

Review 3.  Fluoroquinolone resistance in Neisseria gonorrhoeae.

Authors:  J S Knapp; K K Fox; D L Trees; W L Whittington
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.